Current version snapshot

In clinical trials↗↗↗Metabolic↗

Current · version 4: Petrelintide↗

Related names recorded in this version: ZP8396↗

An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved.↗↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 16, 2026

We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials. 78

What this version reported

A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.↗↗↗

Organizations named in cited records:
  • Hoffmann-La Roche↗
  • Zealand Pharma↗

Trial records: NCT07589686

Reader guide in this version

Key takeaway

Petrelintide, also known as ZP8396, is an experimental amylin analogue developed by Zealand Pharma with Roche, studied for weight management.1,2,3 In ZUPREME 1, a randomized, placebo-controlled Phase 2 trial in 485 adults with obesity, average weight fell by about 8% to 10% at 28 weeks with petrelintide, compared with about 2% with placebo.7 It is not FDA-approved. Phase 3 trials sponsored by Roche were recruiting in late 2026, and none of the sources reviewed here reports an approval in any country.5,6,8

At a glance

What it is
An investigational amylin analogue, also known as ZP8396, from Zealand Pharma and Roche.1,2,3
FDA status
Not FDA-approved. Three Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.5,6,8
Human evidence
One published randomized, placebo-controlled Phase 2 trial in 485 adults, and two small randomized Phase 1 trials. A second Phase 2 trial, in type 2 diabetes, is listed as completed without results in the sources cited here.2,4,7
Evidence strength
Large randomized human trials

What is petrelintide?

Petrelintide is an experimental amylin analogue also known by its development code, ZP8396.1,2

ClinicalTrials.gov lists Zealand Pharma as the sponsor of its Phase 2 trials and Hoffmann-La Roche as the sponsor of later trials, including a combination study with Zealand Pharma as collaborator.1,3,4

How is petrelintide thought to work?

Petrelintide is designed as a long-acting analogue of amylin, a hormone involved in appetite. The ZUPREME 1 authors describe its mechanism as distinct from that of incretin-based treatments.2,7

The published trials measured its effects on body weight and side effects, but the sources reviewed here do not establish how it produces those effects in people.2,7

What do human studies show?

ZUPREME 1 randomly assigned adults with obesity, or overweight with high blood pressure or abnormal blood fats, to one of five levels of petrelintide or to placebo for 42 weeks, at 32 sites in Poland, Romania and the United States. Of 493 people randomized, 485 received treatment.7

At 28 weeks, average body weight fell by 7.9% to 9.8% across the petrelintide groups and by 1.7% with placebo. Weight kept falling to week 42, by up to 10.7%.7

Nausea was the most common side effect, in 20% of people on petrelintide and 6% on placebo. Vomiting, diarrhoea and constipation were reported at low rates in both groups, and no deaths were reported. Zealand Pharma funded the trial, and several authors are its employees.7

Earlier, two small randomized, placebo-controlled Phase 1 trials described weight reductions and no serious or severe adverse events that emerged during treatment.2

ClinicalTrials.gov also lists a Phase 1 study in people with reduced kidney function, completed as of its January 28, 2026 record. None of these trials can show long-term benefit or rule out uncommon harms, which the Phase 3 program is registered to study.5,6,9

What the evidence base contains

  • Large randomized human trial ZUPREME 1 (NCT06662539): a multicentre, randomized, double-blind, placebo-controlled Phase 2 trial in 485 adults with obesity, or overweight with high blood pressure or abnormal blood fats, without type 2 diabetes, followed for 42 weeks; the main result was weight change at 28 weeks.7
  • Controlled human trial Two randomized, blinded, placebo-controlled Phase 1 trials, one following participants for 16 weeks, in normal-weight, overweight or obese adults. The published abstract does not give total enrollment.2
  • Registered trial without results A Phase 2 trial in overweight or obesity with type 2 diabetes (NCT06926842), sponsored by Zealand Pharma and listed as completed in its September 9, 2026 registry record.4
  • Registered trial without results ZUPREME-5 (NCT07843472), ZUPREME-4 (NCT07843485) and a third Phase 3 trial in obesity or overweight (NCT07843498), sponsored by Roche and listed as recruiting in their October and November 2026 registry records.5,6,8

Evidence-strength label: Large randomized human trials. How this label is assigned

Is petrelintide FDA-approved?

No. Petrelintide remains in clinical trials. None of the sources reviewed here reports an approval of petrelintide in any country.5,6,7,8

As of their retained registry records, ZUPREME-5 (October 7, 2026), ZUPREME-4 (November 5, 2026) and a third Phase 3 trial in obesity or overweight (November 5, 2026), all sponsored by Roche, were listed as recruiting.5,6,8

A Phase 2 combination study with enicepatide, sponsored by Roche, was listed as not yet recruiting in its July 7, 2026 record.1

Timeline

  1. Results of two randomized Phase 1 trials of petrelintide are published.2
  2. ClinicalTrials.gov lists the ZUPREME Phase 2 obesity trial as completed.3
  3. ClinicalTrials.gov lists a Phase 2 trial in overweight or obesity with type 2 diabetes as completed.4
  4. Results of the ZUPREME 1 Phase 2 trial are published online in The Lancet Diabetes & Endocrinology.7
  5. The retained ClinicalTrials.gov record of the ZUPREME-5 Phase 3 trial lists it as recruiting.5
  6. The retained ClinicalTrials.gov records of ZUPREME-4 and a third Phase 3 trial list them as recruiting.6,8

What is still unknown?

What the completed Phase 2 trial in people with type 2 diabetes found: its results are not part of the sources cited here.4

Its effects and safety over longer periods and in larger groups, including people with cardiovascular disease or type 2 diabetes, which the Phase 3 trials are registered to study.5,6,8

Sources for this version

  1. 1
    Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials (2026) · PMID 42017294 ↗

    Diabetes, Obesity and Metabolism · Official source · Source checked November 14, 2026

  3. 3
    ClinicalTrials.gov record NCT06662539 · retained source version 2026-03-23:25a9d8533efb66766440e5abf5b03342f70235dae33ae71a773e757bb8847402 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  4. 4
    ClinicalTrials.gov record NCT06926842 · retained source version 2026-09-09:66566db76c0ba35707f571957d43a26bb1a34c1cb277263d2109ca1fdebaf137 ↗

    ClinicalTrials.gov · Official source · Source checked September 9, 2026

  5. 5
    ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  6. 6
    ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  7. 7
    Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial (2026) · PMID 42810355 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 16, 2026

  8. 8
    ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  9. 9
    ClinicalTrials.gov record NCT07076030 · retained source version 2026-01-28:68a10be352b494ee43c532b4782a5eda7e3dc609ba1c5da1829378a353712497 ↗

    ClinicalTrials.gov · Official source · Source checked September 9, 2026